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Abstract 
Cidofovir is a new class of antiviral agent with potent in vitro and in vivo activity 
against a broad spectrum of herpes viruses. The aim of this work was to obtain a prolonged 
therapeutic effect of cidofovir in the basal epidermis after its topical application. For this 
purpose, PLGA microparticles were prepared by solvent evaporation and spray-drying 
methods. Microparticles prepared by spray-drying showed a encapsulation efficiency of 80%. 
Conversely, for all the microspheres prepared by the W/O/W solvent evaporation method the 
encapsulation efficiency was low. Also, microparticles prepared by spray-drying showed a 
higher burst release. Skin penetration and distribution experiments were carried out with 
cidofovir-loaded microparticles prepared by spray-drying, since these carriers presented the 
best characteristics in terms of size and encapsulation efficiency. A cidofovir solution in 0.2% 
PVA served for comparison. Penetration experiments were carried out in Franz type diffusion 
cells with an available diffusion area of 1.76 cm2, using porcine skin. The results obtained 
showed that the amount of cidofovir penetrated, over a 24 h time period, was higher with the 
drug solution than with microparticles. Cidofovir distribution in porcine skin, after topical 
application of microparticles and drug solution for 24 h, was determined by horizontal slicing 
of the skin. The profiles obtained for the two formulations showed that the quantity of 
cidofovir retained in the skin decreased with the depth. Besides the amount of cidofovir found 
in the basal epidermis (120-150 μm) was much higher with microparticles than with the 
control solution. These data showed that cidofovir-loaded microparticles could improve 
cidofovir topical therapy since these vehicles increased drug retention in the basal epidermis 
and decreased its penetration through the skin. 
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1. Introduction 
Cidofovir ((1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl] cytosine) (HPMPC)) 
represents a new class of antiviral agent with potent in vitro and in vivo activity against a 
broad spectrum of herpes viruses (Bronson et al., 1990). Unlike acyclovir and other 
nucleoside analogs currently used for clinical therapy of human herpes virus infection, 
cidofovir does not require virally encoded thymidine kinase for conversion to the active 
metabolite, cidofovir diphosphate (De Clercq, 1984). Its ability to protect uninfected cells has 
a great potential in the treatment of recurrent herpes simplex virus infections, HSV-1 and 
HSV-2, where viral outbreaks lead to secondary cell infection (Spruance and Freeman, 1990). 
In this way, topical administration of cidofovir has been shown to be effective in the 
treatment of cutaneous infections of herpes simplex viruses HSV-1 and HSV-2 in animal 
models (De Clercq and Holy, 1991; Maugdal and De Clercq, 1991; Kern et al., 1995). 
Besides, acyclovir-resistant HSV-1 in human provided responsive to treatment with topical 
cidofovir (Snoeck et al., 1993). Consequently, several authors have studied the way to deliver 
greater amounts of this drug to the target site of virus infections, the basal epidermis, in order 
to increase the efficacy of the topical therapy. Therefore, the quantification of cidofovir 
within the skin and after the in vitro percutaneous penetration studies are essential for topical 
and transdermal research (Touitou et al., 1998). 
To minimize systemic exposure and maximize local concentrations, significant effort 
has been devoted to the development of localized antiviral therapy. It has been shown that 
poly(lactide-co-glycolide) (PLGA) microparticles penetrate through the stratum corneum and 
reached the viable epidermis (Gª de Jalón et al., 2001a). These particles were used to deliver 
acyclovir in the basal epidermis (Gª de Jalón et al., 2001b). Other authors have also used drug 
delivery systems for topical delivery of different drugs, such as retinol (Rösseler et al., 1994) 
5-fluorouracil-ethyl (Ghorab et al., 1990) and allergenic substances (Brosse et al., 2000). 
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In the present study, to obtain a prolonged therapeutic effect of cidofovir in the basal 
epidermis after its topical application, PLGA microparticles were prepared by solvent 
evaporation and spray-drying methods. 
 
2. Materials and methods 
2.1 Materials 
Cidofovir was a gift from Gilead Sciences (Foster City, CA, USA). Poly(d,l-lactide) 
(PLA) and Poly(d,l-lactide-co-glycolide) (PLGA) type polymers (PLGA Resomer RG502, 
RG752, RG756 and PLA R202) were purchased from Boehringer Ingelheim (Ingelheim, 
Germany). Polyvinyl alcohol (PVA) was obtained from BDH (Poole, England). 
Dichloromethane (DCM) was from Prolabo (Fontanay, France). Thetrabutylammonium 
dihydrogenphosphate was supplied by Fluka Chemica (Buchs, Switzerland). Acetonitrile, 
disodium hydrogenphosphate and other solvents used were of analytical grade and were 
obtained from Merck (Darmstadt, Germany). 
 
2.2 Preparation of microspheres by W/O/W solvent evaporation 
Cidofovir was dispersed in 0.5 ml of PVA 1% and 0.2 g of polymer was dissolved in 5 
ml of DCM. The suspension and the solution were mixed by ultrasonication under cooling. 
This so-called inner emulsion was slowly added to 30 ml of a 1% PVA solution, which was 
homogenised using an ultraturrax®. The resulting W/O/W emulsion was stirred at room 
temperature for at least three hours to allow solvent evaporation. The microspheres were 
collected by centrifugation (3000 rpm for 10 min, Biofuge stratus Heraeus Instruments, 
Hanau, Germany), washed with distilled water and freeze-dried (Blanco-Príeto et al., 1997). 
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2.3 Preparation of microspheres by spray-drying 
Cidofovir was dispersed in a 5% (w/w) polymer solution in DCM. The suspension was 
spray-dryed through a 0.7 mm nozzle installed in a Mini Spray-Dryer 190 (Büchi, Flawil, 
Switzerland) (Blanco-Príeto et al., 2000). The product feed was 3 ml/min, inlet and outlet 
temperatures were at 50 and 40 °C, respectively, aspirator setting at 40 m3/h, and spray-flow 
at 450 Nl/h.  
 
2.4 Microspheres characterization 
The morphology and size of the microspheres were analyzed by light microscopy 
(Olympus BH-2, Spain) and laser light diffraction (Mastersizer®, Malvern, U.K.). The drug 
content in the microparticles was determined by first dissolving 5 mg of microspheres in 3 ml 
of DCM followed by extraction with 6 ml of 10-4M NaOH. Cidofovir was assayed in the 
aqueous phase spectrophotometrically at a wavelength of 274 nm. 
 
2.5 Burst release 
The drug release after 24 hours (burst release) was determined by dispersing a 
precisely weighed amount of microspheres in 1.5 ml of isoosmolar PBS (pH 7.4, 67 mM 
phosphate). The test media was preserved with 0.02% (w/w) of sodium azide. Incubation took 
place in rotating vials at 37 °C. Each assay was replicated three times. The amount of drug 
released was determined spectrophotometrically.  
 
2.6 In vitro penetration experiments 
Porcine ears from the local slaughterhouse were cleaned with water and the outer 
region of the ear was cut. The whole skin was dermatomed (Aesculap® Tuttlingen, Germany) 
to 1.2 mm and immediately frozen at –20ºC. The skin samples were clamped between the two 
chambers of Franz diffusion cells, with an available diffusion area of 1.76 cm2 (FDC-400, 
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Grown Glass Company, Somerville, USA). The stratum corneum faced the donor 
compartment and the dermis the receptor one. 
After stabilisation of the skin, 1.5 mL of microparticles containing cidofovir (15 mg) 
or the drug solution (15 mg) were placed, on the skin surface, in the donor compartment. The 
receptor compartment was filled with 11 mL of phosphate buffer solution (pH 6), maintained 
at 37±1ºC and stirred at 600 rpm using magnetic stirring bars. 400 μL aliquots were collected 
from the receptor side at designated time intervals, for a 24 h period, and replaced with the 
same volume of fresh buffer.  
The amount of cidofovir in the receiver phase samples was analysed by high-
performance liquid chromatography (HPLC Hewlett-Packard 1050) with ultraviolet detection 
(λ=274 nm). The column used was a reversed-phase 250x4 mm C8 LiChrospher Select B      
(5 μm) provided by Merck. The mobile phase consisted on 3% of acetonotrile and 97% of 1.5 
mM of tetrabutylamonium dihydrogen phosphate and 3.5 mM of disodium 
hydrogenphosphate adjusted to pH 6.0 with concentrated phosphoric acid. This HPLC method 
has been previously validated. 
 
2.7. Skin sectioning and cidofovir extraction 
The amount of the drug retained, in different strata of the skin, was performed by 
horizontal slicing of the skin in a freeze microtome (2800 Frigocut E, Reichert-Jung, 
Germany). After permeation experiments, the skin was removed from the diffusion cell and 
rinsed with distilled water. The treated skin area (1.76 cm2) was frozen in liquid nitrogen and 
cut with the freeze microtome in order to get horizontal slices of 90 μm. Cidofovir was 
extracted from the slices with 300 μL of distilled water at 60±5ºC for 15 min. Then, the 
mixture was centrifuged at 8000 rpm (Biofuge Stratus Heraeus Instruments, Germany) and 
the extract analysed by HPLC. The HPLC conditions were the same described above. 
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For the calibration of the extraction procedure, blank samples of skin slices, from 
different animals and depths, were spiked with three different known amounts of cidofovir 
solution, and after 3 h of contact, were extracted as previously described. The extraction 
recovery was measured by comparing the amount of cidofovir added and extracted. 
Satisfactory recoveries were obtained from all samples tested (≥94%). Cidofovir 
concentration was expressed as μg of cidofovir /cm3 of skin. 
 
3.  Results and discussion 
3.1 Microspheres characteristics 
In this study, cidofovir was encapsulated into PLA/PLGA microspheres mainly by 
the W/O/W solvent evaporation method but also by spray-drying. The nominal amount of 
cidofovir for all the preparations was 10%, relative to the PLA/PLGA-mass. The mean 
diameter of the resulted cidofovir-loaded microspheres are listed in table 1. Microspheres 
prepared by the W/O/W solvent evaporation method using different copolymers showed a 
mean diameter of 5.2, 5.7, 5.9 and 8.7 μm depending on the polymer utilized en their 
preparation (table 1). The copolymer with the higher molecular weight (RG756) produced 
organic solution with higher viscosity, resulting in microspheres with the larger diameter (8.7 
μm). By spray-drying, PLGA particles showed a slightly lower diameter (table 1).  
The encapsulation efficiency was significantly higher with spray-drying than with 
solvent evaporation (table 1). Actually, particles prepared by spray-drying showed an 
encapsulation efficiency of up 80%. Conversely, for all the microspheres prepared by W/O/W 
solvent evaporation method the encapsulation efficiency was low (table 1). The relative 
modest encapsulation efficiency achieved can be ascribed to a certain solubility of cidofovir 
in the organic phase and the leakage of cidofovir to the external aqueous phase where most of 
the drug was found. Indeed, a key parameter for the successful encapsulation of drugs by this 
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method is the insolubility of the drug in the organic polymer solution (Blanco-Príeto et al., 
1998).  
Besides, it has been shown that increasing the amount of polymer in the organic 
phase augmented the encapsulation efficiency (Hermann et al., 1995), since raising the 
amount of polymer increased the viscosity of the primary W/O emulsion. This high viscosity 
stabilized the internal aqueous phase against coalescence and hence reduced drug loss to the 
external aqueous phase. In our case, no significant changes in cidofovir encapsulation 
efficiency was observed when the polymer concentration in the organic phase was augmented 
(results not shown). 
 
3.2 Burst release 
The in vitro release of cidofovir from microparticles after 24 hours (burst release) is 
presented in figure 1. For microparticles prepared by W/O/W solvent evaporation method, the 
release of cidofovir was independent of the ratio of PLA/PLGA and slightly attenuated when 
microspheres were prepared with the higher molecular weight copolymer (98000 Da) (figure 
1). This results are in agreement with previous studies (Blanco-Príeto et al., 1997). 
Microparticles prepared by spray-drying showed a higher burst release than those 
made by W/O/W solvent evaporation technique (figure 1). This might be explained by the 
difference in the encapsulation efficiency. The rate of drug release tends to augment with an 
increased drug content in the particles (Sah et al., 1994; Ertl et al., 1999), due to incrasing 
amounts of drug located at the suface of the microspheres.  
 
 
3.3 Skin penetration and distribution of cidofovir-loaded microparticles 
Since cidofovir-loaded PLGA microparticles prepared by spray-drying showed the 
best characteristics for topical application (smallest size and the higher encapsulation 
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efficiency), these microparticles were used for skin penetration and distribution experiments. 
Also, in a previous work, it has been shown that PLGA microparticles can penetrate through 
the stratum corneum and reached the basal epidermis, the target site of the HSV-1 infections 
(Gª de Jalón et al., 2001a). 
Porcine skin, specifically the outer region of the ear, was chosen since its use for 
permeation experiments has been extensively documented (Bathia and Sing, 1998) and it is 
well suited for representing the human skin permeability (Simon and Maibach, 2000).  
In order to study the penetration of the microparticles, 1,5 mL of the formulation (15 
mg of cidofovir) were placed on the skin surface in the donor compartment and 400 μL 
aliquots were collected from the receptor side of the diffusion cell at designated intervals (2, 
8, 16 and 24 h). A cidofovir solution in 0.2% PVA (15 mg) served for comparison. To 
confirm membrane barrier integrity during the time of the experiment, the skin was observed 
by light microscopy before and after the permeation experiments, and no skin structural 
alterations were found. 
The penetration profiles of cidofovir from the two formulations, over a 24 h time 
period, are shown in figure 2. Cidofovir mean flux values at steady state from microparticles 
and control solution were 3.63±0.22 and 5.27±0.31 μg/cm2h respectively. This result 
indicated that cidofovir penetration through porcine skin was higher from the drug solution 
than from microparticles.  
At the end of the penetration experiments, cidofovir distribution into the porcine skin, 
after topical application of microparticles and control solution, during 24 h, was determined 
by horizontal slicing of the skin. Figure 3 shows the quantity of cidofovir detected, in the 
different strata of the skin, 24 h after topical application of microparticles (15 mg of 
cidofovir) and the control solution (15 mg of the drug). It has been previously reported that in 
the porcine skin, the upper 100 μm represented mainly the stratum corneum and upper layers 
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of viable epidermis, between 100 to 200 μm consisted basically of viable epidermis and 
dermis was located from 200 to 500 μm (Jenning et al., 2000a). The distribution profiles 
obtained for the two formulations showed that the quantity of cidofovir retained in the skin 
decreased with the depth. The amount of cidofovir found in the first layers of the skin (to 180-
270 μm of depth) was higher with microparticles than with the control suspension, although 
from 270 to 800 μm there were no significant differences between the two formulations. This 
result could be explained because microparticles can penetrate through the stratum corneum 
and reach the epidermis in a relatively high number (Gª de Jalón et al., 2001a). Also, this 
higher cidofovir concentration in the first skin layers could be due to an occlusive effect, 
since microparticles produced a film on the skin surface, which reduces the transepidermal 
water loss and favours drug penetration into the skin. The same feature has been observed 
using acyclovir-loaded microparticles (Gª de Jalón et al, 2001b) and solid lipid nanoparticles 
(Jenning et al., 2000b). 
According to the skin morphology of the different slices and the data previously 
reported, it was assumed that basal epidermis (site of herpes virus lesions) was located 
between 120 and 150 μm. Consequently, at the basal epidermis, the quantity of cidofovir 
found with microparticles was higher than with the solution and this fact pointed out the 
relevance of these microparticles for cidofovir topical delivery.  
 
4. Conclusion 
Cidofovir-PLGA microparticles were prepared by spray-drying and by a W/O/W 
solvent evaporation method. Spray-dried microspheres showed the best characteristics to 
perform percutaneous penetration studies in terms of size and encapsulation efficiency. Skin 
penetration and distribution experiments, at 24 h, showed that cidofovir-loaded microparticles 
increased drug retention in the basal epidermis and decreased its penetration through the skin. 
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Consequently, these microparticles could represent a good vehicle to supply the skin with the 
drug during a prolonged period of time. More experiments are underway to study the 
percutaneous penetration of cidofovir and cidofovir-loaded microparticles in 48 and 72 hours. 
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Figure legends 
 
Figure 1. In vitro release of cidofovir from PLGA microspheres in PBS (t=24 hours). *Spray-
dryed microparticles 
 
Figure 2. Amount of cidofovir penetrated through porcine skin after 24 h, from 
microparticles and control solution. Each point represents the mean value±S.D. (n=3). 
 
Figure 3. Distribution of cidofovir, in porcine skin layers, following topical administration of 
microparticles and control solution for 24 h. Each point represents the mean value±S.D. 
(n=3). 
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Table 1: Encapsulation efficiencies and size of different microparticles formulations. 1SE: 
solvent evaporation method; SD: spray-drying 
Polymer Polymer Mw Preparation 
method1
E.E.(%) Mean 
diameter (μm) 
RG502 12000 SE 10±5 5.2 
RG502 12000 SD 80±10 3.6 
RG752 16000 SE 13.6±3 5.7 
RG756 98000 SE 14±3 8.7 
R202 16000 SE 12.1±5 5.9 
 
 
 17
 
 
 
0
10
20
30
40
50
60
RG502 RG502* RG752 RG756 R202
Bu
rs
t (
%
)
 
 
 18
0
40
80
120
160
0 4 8 12 16 20 24
Time (h)
C
D
 p
er
m
ea
te
d 
( μg
/c
m
2 ) suspension
microparticles
 
 19
 
0
500
1000
1500
2000
2500
0-90 90-180 180-270 270-360 360-450 450-540 540-630 630-720 720-810
Depth (μm)
C
id
of
ov
ir 
in
 s
ki
n 
( μg
/c
m
3 )
Suspension
Microparticles
 
 
 
 
 
